Veru (VERU)

• Market cap: $36M
• 1 day: 0.9%
• 5 days: -4.27%
• 1 month: -28.43%
• 3 months: -0.44%
• 6 months: -12.84%
• Year to date: -1.32%
• 1 year: -53.81%
• 5 years: -96.83%
• 10 years: -83.16%
• Sector: Healthcare
• Industry: Biotechnology

About: Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Employees: 20